BridgeBio Oncology Therapeutics, Inc.

BridgeBio Oncology Therapeutics, Inc., trading under the ticker BBOT, is a clinical-stage oncology biopharmaceutical company operating in the healthcare and life sciences sector. The company filed a 424B3 prospectus with the U.S. Securities and Exchange Commission on May 13, 2026, under accession number 0001193125-26-221560, a form type typically used to deliver a final prospectus to investors in connection with a registered securities offering. BBOT represents part of the ongoing wave of oncology-focused entities accessing public markets through structured capital vehicles. Full filing details, historical pricing data, and deal-level analytics for BBOT are available on SpacDesk — sign up at SpacDesk.com to access the complete dataset.